Results 31 to 40 of about 5,389 (186)

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. [PDF]

, 2019
Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency ...
Li, Hui, Liu, Hong, Liu, Jing, Liu, Juan, Liu-Smith, Feng, Roy, Mridul, Sun, Shuming, Wang, Zi, Xiao, Xiaojuan, Ye, Mao, Zhang, Bin, Zhang, Hui, Zhang, Yibin, Zhou, Weihua   +13 more
core   +1 more source

The evolutionary landscape of treatment for BRAFv600e mutant metastatic colorectal cancer [PDF]

, 2021
The BRAFV600E mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months.
Amatu A., Bencardino K., Bonazzina E., Cipani T., Ghezzi S., Gori V., Massihnia D., Mauri G., Sartore Bianchi A., Siena S., Spina F., Tosi F.   +11 more
core   +1 more source

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF^V600E Protein

Molecules, 2022
BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma; however, their long-term efficacy is hampered by ...
Elisabetta Marini, Marco Marino, Giulia Gionfriddo, Federica Maione, Marta Pandini, Daniele Oddo, Marta Giorgis, Barbara Rolando, Federica Blua, Simone Gastaldi, Serena Marchiò, Sandra Kovachka, Francesca Spyrakis, Eleonora Gianquinto, Federica Di Nicolantonio, Massimo Bertinaria   +15 more
doaj   +1 more source

Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance

Journal of Cutaneous Immunology and Allergy, 2023
While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug‐associated retinopathy has become an emerging adverse event.
Takumi Hasegawa, Shiro Iino, Misako Fujisaki, Sayuri Okamura, Natsuki Baba, Nami Tanaka, Yuko Takeuchi, Noritaka Oyama, Minoru Hasegawa   +8 more
doaj   +1 more source

Clinical proteomics for precision medicine: the bladder cancer case [PDF]

, 2017
Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of –omics based approaches.
Frantzi, Maria, Latosinska, Agnieszka, Merseburger, Axel S., Mischak, Harald, Vlahou, Antonia   +4 more
core   +1 more source

MicroRNAs in melanoma development and resistance to target therapy [PDF]

, 2017
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio, Ciliberto, Gennaro, Costantini, Susan, Croce, Carlo M, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco   +7 more
core   +1 more source

Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature

Current Problems in Cancer: Case Reports, 2021
Encorafenib/binimetinib combination is approved for BRAF mutated melanoma and is being increasing used. The landmark COLUMBUS trial reports
Nabin Raj Karki, Himax Patel, Luvika Gupta, Nagla Abdel Karim   +3 more
doaj   +1 more source

Clinical implications of epithelial cell plasticity in cancer progression [PDF]

, 2015
Mini-review[Abstract] In the last few years, the role of epithelial cell plasticity in cancer biology research has gained increasing attention. This concept refers to the ability of the epithelial cells to dynamically switch between different phenotypic ...
Antón-Aparicio, Luis M., Blanco, Moisés, Calvo, Lourdes, Castosa, Raquel, Concha, Ángel, Figueroa, Angélica, Valladares-Ayerbes, Manuel   +6 more
core   +2 more sources

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design [PDF]

, 2022
BRAF V600 mutation; Binimetinib; EncorafenibMutació de BRAF V600; Binimetinib; EncorafenibMutación de BRAF V600; Binimetinib; EncorafenibBRAFV600 oncogenic driver mutations occur in 1–2% of non-small-cell lung cancers (NSCLCs) and have been shown to be a
Ahn, Myung-Ju, Felip Font, Enriqueta, Ramalingam, Suresh, Riely, Gregory, Smit, Egbert, Tsao, Anne   +5 more
core   +1 more source

Drug-perturbation-based stratification of blood cancer [PDF]

, 2018
As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown.
Dietrich, Sascha, et al, Rossi, Davide, Zenz, Thorsten   +3 more
core   +1 more source